Dr. Kim is an accomplished healthcare industry leader who has made significant contributions across the biotechnology and financial industries during his career at Moderna and Goldman Sachs. He has extensive operational expertise and an extraordinary track record in raising capital for high-growth health care companies.
Dr. Kim is a co-founder and managing partner of Ascenta Capital. Previously, he served as a venture partner at Third Rock Ventures. Dr. Kim was previously the chief financial officer of Moderna, Inc., where over six years from April 2014 to June 2020, he was instrumental in raising $4.4 billion in capital to support the company’s platform efforts in mRNA therapeutics and the development of its pipeline of more than 20 drug candidates spanning oncology and other therapeutic areas. Before joining Moderna, Dr. Kim had a highly productive 14-year career at Goldman Sachs, where he advised numerous companies as a managing director and co-head of biotechnology investment banking.
Dr. Kim currently serves on the boards of directors of AmerisourceBergen Corporation, ADARx, Inc., Flare Therapeutics, Inc., and Abata Therapeutics, Inc. and previously served on the board of directors of Seres Therapeutics, Inc. He is also on the Board of Governors of the American Red Cross. Dr. Kim received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. in healthcare management from the Wharton School of the University of Pennsylvania and an A.B. in biochemical sciences from Harvard University.
What is Lorence H. Kim's net worth?
The estimated net worth of Lorence H. Kim is at least $2.67 million as of July 22nd, 2022. Dr. Kim owns 60,500 shares of Revolution Medicines stock worth more than $2,665,630 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Kim may own. Learn More about Lorence H. Kim's net worth.
How do I contact Lorence H. Kim?
Has Lorence H. Kim been buying or selling shares of Revolution Medicines?
Lorence H. Kim has not been actively trading shares of Revolution Medicines within the last three months. Most recently, on Friday, July 22nd, Lorence H. Kim bought 50,000 shares of Revolution Medicines stock. The stock was acquired at an average cost of $20.00 per share, with a total value of $1,000,000.00. Following the completion of the transaction, the director now directly owns 60,500 shares of the company's stock, valued at $1,210,000. Learn More on Lorence H. Kim's trading history.
Who are Revolution Medicines' active insiders?
Revolution Medicines' insider roster includes Jack Anders (Insider), Jeff Cislini (General Counsel), Mark Goldsmith (Insider), Margaret Horn (COO), Stephen Kelsey (President, Research & Development), Lorence Kim (Director), Vincent Miller (Director), Sushil Patel (Director), Thilo Schroeder (Director), Peter Svennilson (Director), Xiaolin Wang (Insider), and Barbara Weber (Director). Learn More on Revolution Medicines' active insiders.
Are insiders buying or selling shares of Revolution Medicines?
In the last twelve months, Revolution Medicines insiders bought shares 1 times. They purchased a total of 1,304,347 shares worth more than $59,999,962.00. In the last twelve months, insiders at the sold shares 28 times. They sold a total of 271,841 shares worth more than $11,976,056.91. The most recent insider tranaction occured on December, 16th when COO Margaret A Horn sold 4,329 shares worth more than $196,536.60. Insiders at Revolution Medicines own 8.0% of the company.
Learn More about insider trades at Revolution Medicines. Information on this page was last updated on 12/16/2024.
